Background. Kidney transplant recipients are at high risk of opportunistic infection. The aims of this study were to describe the epidemiology, clinical features and prognosis of Tuberculosis (TB) in kidney transplant recipients. Methods. Retrospective observational study conducted in 14 French transplant centres involving all cases of TB that occurred in kidney transplant recipients between 1986 and 2006. Results. Among the 16146 kidney transplantations performed during the study period, 74 (0.45%) developed TB. The country of birth was a highly endemic area for TB in 20 (40.8%) patients. Time from kidney transplantation to TB was 10 months (4-27). Extrapulmonary and disseminated TB accounted for 33 (67.4%) cases. The most common symptoms were fever (71.7%), weight loss (41.3%) and asthenia (39.1%). Coexisting infections were diagnosed in 11 (22.4%) patients. Microbial sensitivity tests revealed no case of multidrug-resistant TB. Haemophagocytic syndrome associated with TB was diagnosed in 5 (10.2%) cases with 60% of mortality (P ¼ 0.0005). Median length of antituberculous therapy was 12 (9.5-12) months. Immunosuppressive therapy was reduced in 22 (44.9%) patients without adverse consequence on the graft. Overall, hospital mortality was 6.1% and 1-year graft survival was 97%. Conclusions. Kidney transplantation increases the risk of TB, with a high rate of extrapulmonary disease. Symptoms of infection are often attenuated, leading to delayed diagnosis. Overall prognosis is good but haemophagocytic syndrome is associated with high mortality. Country of birth might be taken into account in the decision of post-transplantation treatment of latent TB.
Introduction
Kidney transplantation improves quality of life and overall survival at a lower cost compared to dialysis in patients with end-stage renal disease [1, 2] . Over the past two decades, the development of new immunosuppressive drugs and advances in the understanding of drug management and immune modulation have reduced the incidence of acute rejection episodes and significantly improved long-term outcomes [3] [4] [5] . These advances have prompted increased use of kidney transplantation and substantial broadening of eligibility criteria for both donors and recipients [6] [7] [8] .
Long-term exposure to induction and maintenance immunosuppressive therapy used to prevent graft rejection carries a risk of infection, cancer, and drug-related toxicities in transplant recipients [9] [10] [11] . High-dose immunosuppressive therapy for acute rejection episodes significantly increases these life-threatening complications. Furthermore, in addition to long history of chronic renal disease and dialysis, kidney transplant recipients often have severe co-morbidities (i.e. cardiovascular disease and diabetes) that are associated with specific immune deficiencies.
Tuberculosis (TB) is the predominant infectious cause of morbidity and mortality worldwide, infecting 8.9 million and killing 1.7 million people annually [12] . Kidney transplant recipients have a higher risk of mycobacterial infection than the general population, because immunosuppressive therapy impairs microbial specific cytotoxic T-cell response, a key host defense against mycobacterial infection. Recipients are predisposed to primary infections, but also at risk for reactivating latent infections acquired before transplantation or potentially infection transmitted by the donor [13] . Clinical diagnosis may be difficult and delayed since symptoms are often reduced and presentation atypical. Appropriate treatment with simultaneous management of antituberculous and immunosuppressive drugs remains subject to debate.
The objective of this study was to describe the incidence, clinical features and prognosis of Mycobacterium tuberculosis infection following kidney transplantation. We also reviewed the cases of M. tuberculosis-associated haemophagocytic syndrome (HPS), a rare but potentially life-threatening complication with scarce data in the literature. The impact of antituberculous and immunosuppressive therapies management on the graft and on the infectious process evolution was analysed in this centre study over a 20-year period.
Materials and methods
This retrospective non-interventional study was carried out in 14 French transplant centres (Appendix 1 in online supplement). The French Society of Nephrology approved this study and waived the need for informed consent. All adult recipients of a kidney transplant in the selected centres between 1 January 1986 and 31 December 2006 were screened. Patients were identified by cross referencing the results extracted from the databases analysis of kidney transplantation, microbiological and histopathological departments. Each medical chart was then reviewed for the diagnosis of TB infection in the post-transplant period. The inclusion criteria were: -Microbiological identification by conventional methods: acid-fast bacilli present on the Ziehl-Neelsen-stained smear with a positive culture (M. tuberculosis) on the Lowenstein-Jensen medium.
-or typical histology with specific tuberculous granulomata on histopathological examination of biopsy samples Data collected for analysis included: demographic features, causes of end-stage renal disease, characteristics of transplantation, immunosuppressive regimen, acute rejection episodes, cytomegalovirus (CMV) disease, graft function and clinical features of TB infection (previous history of active TB, treatment of latent TB in post-transplantation symptoms of TB, median time of onset since transplantation, diagnostic methods, concomitant infections, immunosuppressive regimen changes, type and duration of antituberculous therapy). Data reported in Tables 1-3 were abstracted from the medical charts.
Sensitivities to the traditional (isoniazid, rifampicin, ethambutol and pyrazinamide) and second-line (quinolones, aminoglycosides) antituberculous drugs were reported when available (Table 3) . TB-associated HPS was considered among the patients fulfilling the HLH-2004 criteria [14] .
The management of immunosuppressive therapy (unchanged, reduced or withdrawal) during the treatment of TB was at the discretion of the attending physicians. The treatment of TB, its effectiveness, its side effects and its pharmacologic interactions were recorded. The evolution of the infectious process and its effects on the graft and the patient's survival (cured, death or treatment failure defined as continued or recurrently positive cultures in a patient receiving appropriate chemotherapy [15] ) were also recorded. We report on the patients with complete follow-up and no missing data.
Statistical analysis
Results are described as medians and interquartile range (25th-75th percentiles) for quantitative variables or numbers and percentages for qualitative variables. Categorical variables were compared between survivors and decedents using exact Fisher test as appropriate. All tests were two sided, and P values <0.05 were considered statistically significant. Graft and patient survival analysis was performed using the Kaplan-Meier method.
Results
Among the 16146 patients who received a kidney allograft at the 14 participating centres during the study period, 74 (0.45%) were diagnosed for post-transplant TB. TB incidence was equally distributed over the study period (Appendix 2 in online supplement). We report on the 49 patients with no missing data after hospital discharge ( Figure 1 ).
Patient characteristics are reported in Table 1 . The country of birth was an area highly endemic for TB in 20 (40.8%) patients. No patient had the human immunodeficiency virus infection. At admission, all recipients were receiving immunosuppressive therapy, usually with calcineurin inhibitors (85.7%) combined with mycophenolate mofetil (59.1%) or azathioprine (32.6%) and steroids (100%). Eighteen patients (36.7%) had a previous history of acute rejection and 13 (26.5%) had been treated for CMV disease (eight patients had both). Laboratory findings indicated a median serum creatinine level of 135.5 lmol/L (105-189.5) at admission. Table 2 reports the clinical features and outcomes according to the affected organ. Nine (18.4%) patients had a history of active TB with successful treatment before transplantation reported in the medical chart. Time from kidney transplantation to TB was 10 months (4-25). Main reported symptoms were fever (71.7%), weight loss (41.3%) and asthenia (39.1%). Extrapulmonary and disseminated TB accounted for 33 (67.4%) cases. Prior diagnosis, 8.2% of patients reported post-transplantation exposure to TB. Transmission from an infected donor accounted for one case. Microbiological samples yielded the diagnosis in 36 patients and histopathological examination of biopsy samples in 13 patients. Drug susceptibility test results were available for 18 patients and revealed no case of multidrug-resistant TB. The rate of resistance of first-line antituberculous drugs was 11.1% (Table 3) . Sixteen coexisting infections were diagnosed in 11 (22.4%) patients. Bacterial infection was the most associated diagnosis (n ¼ 7), with three allograft pyelonephritis (Citrobacter, Klebsiella oxytoca, Serratia), two pneumonia (without microbiological documentation), one septicemia (Klebsiella pneumoniae) and one cellulitis (Escherichia Coli). Viral infections accounted for five cases: two herpes simplex virus-1 (vesicular lesions on the skin or mouth), two Varicella-Zoster virus (Herpes zoster) and one human herpes virus-8 (Kaposi sarcoma). Opportunistic agents accounted for four cases: two atypical mycobacterium infections, one cryptococcemia and one giardiasis. Histopathological analysis of liver biopsy yielded the diagnosis in 80% of miliary when acid-fast bacilli failed to be isolated.
TB-associated HPS was diagnosed in five (10.2%) patients, corresponding to three disseminated TB (miliary) and two focal pulmonary involvements. Prognosis was poor with 60% of mortality (P ¼ 0.0005). None had received specific therapies in addition to antituberculous drugs to treat HPS (i.e. high dose of steroids or etoposide-based chemotherapeutic regimen). Overall, hospital mortality was 6.1%, 4 (8.1%) patients experienced treatment failure and 85.7% had a favourable outcome.
Patients were treated for 12 (9.5-12) months, with a combination of 3 or 4 antituberculous drugs (rifampicin, isoniazid, pyrazinamide and ethambutol) during the first 3 (2-4) months. Eleven (22.4%) patients were successfully treated with short-course therapy of 6 to 9 months. Systemic steroids were used in two (4.1%) cases: one meningitis and one compressive mediastinal lymphadenopathy. Five (10.2%) patients were treated without rifampicin because its interaction with calcineurin inhibitors was feared. Second-line drugs (quinolones, aminoglycoside and clarithromycin) were added in 12 (24.5%) patients because of first-line drug resistance or side effect, severe clinical condition or co-infection with atypical mycobacteria. Sixteen (32.6%) patients experienced side effects of treatment, mainly optic neuritis (10.2%), hepatitis (6.1%) and neuropathy (6.1%).
Immunosuppressive regimen was reduced for 22 (44.9%) patients without adverse consequence on the graft. When the clinical conditions did not warrant a reduction of immunosuppression, the dose of cyclosporine or tacrolimus had to be increased 2-to 5-fold in order to maintain stable blood levels, in all cases where rifampicin was used.
As shown in Figure 2 , graft survival rates analysed by Kaplan-Meier were 97, 85 and 67%, at 1, 5 and 10 years, respectively. Among causes of graft loss (n ¼ 18), death with functioning graft accounted for three patients and acute or chronic rejection for 13 patients.
Discussion
In our study, 0.45% of the 16146 kidney transplant recipients from 14 participating centres experienced posttransplantation TB. This is in accordance with the prevalence reported in United States transplant centres ranging from 0.3 to 1%, and slightly lower than the 0.8 to 3% reported in Spanish studies [16] [17] [18] . Higher rates have been reported in South Africa, India, Turkey and Pakistan where TB affects 5 to 15% of transplant populations [19] [20] [21] [22] [23] . This discrepancy obviously reflects the difference in the overall incidence of TB in the general population of these countries. Even if it remains low in France, this risk is~30 times higher than the risk in the general population. Interestingly, we report that all patients had steroids in their immunosuppressive regimen and that 40.8% of them were born in an area highly endemic for TB. The role of corticosteroids in reactivation of TB, either in pulse high-dose or low-dose chronic use, has been well known and documented [24, 25] . In our study, TB occurred in the first post-transplant year. These findings support the common assumption that TB is thought to arise by reactivation of old foci of infection, enhanced by immunosuppressive therapy [18, 26] . Indeed, only 8.2% were documented as primary infection and transmission from the donated organ remained exceptional and accounted for one case.
Nevertheless, it may seem surprising that a previous history of active TB was reported in the medical chart in <20% of patients, tuberculin skin testing was performed in only 12.2% of cases (of which 50% had reactivity), and 4.1% received treatment for latent TB by isoniazid in the early post-transplantation period. This may be explained by the fact that the recommended screening strategy for TB in renal transplant candidates has significant limits [13, 27] . Several studies reported the lack of sensitivity and specificity (~50%) of tuberculin skin testing to indicate latent TB in patients with end-stage renal disease, explained by impairment of cell-mediated immunity [28, 29] . Similarly, searching several decades ago for a history of TB or looking for images suggestive of past TB infection on chest X-ray may be faulted. Conversely, taking into account, the country of birth is not currently recommended. The recommendations from the European Best Practice Guidelines for Renal Transplantation and the American Society of Transplantation are for a 9-month course of isoniazid for the treatment of latent TB [13, 27] . Recent studies point its benefit in preventing post-transplant TB in endemic areas without significant adverse effect [30, 31] . From our study, we believe that the country of birth is one criterion that should be evaluated in the decision to provide a treatment for latent TB. According to previous studies, we report that active TB was mostly diagnosed in the 'late' (>6 months) post-transplant period but within the first year (median: 10 months). It should be taken into account that: (i) unusual clinical pattern could have led to delayed diagnosis; (ii) TB is an infectious disease with a slow evolution and (iii) TB in transplant recipients arise by reactivation of previous infection and induction immunosuppressive therapy at the time of transplantation could triggered the disease. For these reasons, treatment of latent TB should be implemented over the first trimester of kidney transplantation management.
It was difficult to recognize TB in kidney recipients since symptoms were often diminished and the clinical pattern unusual. For instance, more than a quarter of patients had no fever and this could have led to delayed diagnosis. The main clinical difference with the non-immunosuppressed population was that two-thirds of patients had extrapulmonary or disseminated TB, compared with only~20% of cases in normal hosts [32] . These results are in accordance with previous studies [20, 33, 34] . It is interesting to underline that histopathological analysis of liver biopsy was a useful tool, notably in disseminated forms when repeated bacteriological samples did not allow a definitive diagnosis. High rates of mortality (20-30%) and graft loss have been reported in previous studies [16, 18, 20, 34] . This was not our experience with 6.1% of mortality. As shown in Figure 2 , the graft survival at 10 years was 67%; these data are comparable to those published in the annual reports of the French agency of biomedicine among all kidney transplant recipients on the same study period (64.1% at 10 years) [35] . Inequalities in coverage between countries can probably partly explain these results, with their impact on length of hospital stay and treatment costs borne by patients.
To our knowledge, we are the first to report the incidence of HPS in a cohort of patients experiencing TB after renal transplantation. HPS is rare and was first described in 1979 by Risdall et al. [36] . This syndrome can occur in all age groups in association with many diseases, including malignancies, connective tissue disease, infections and genetic abnormalities [37] . Most authors agree that immunocompromised patients are more prone to develop this syndrome. HPS can be life threatening, and the reported prognosis is poor [38, 39] . Main causes of death are multiple organ failure, bleeding and sepsis. Symptoms are fever, Meningitis and central nervous system (n
Continued or recurrently positive cultures in a patient receiving appropriate chemotherapy. enlargement of the liver and spleen, cytopenias (anaemia, thrombocytopenia and leucopenia) liver dysfunction, high serum levels of triglycerides and ferritin and histological evidence of haemophagocytosis on bone marrow smear examination [40, 41] . Because HPS is rare, its incidence is difficult to accurately assess. Few case reports have been described among renal transplant recipients. In the only available series of 17 cases reported by Karras, mortality rate was 47% and graft loss occurred in 44.4% of survivors [42] . Viral infection was the most frequent condition associated with HPS (52.9%) and only two cases of TB were reported. In our series, 10.2% of patients experienced TB-associated HPS, with 60% of mortality. Causes of death were multiple organ failure in two cases and bleeding (stroke) in one case. In 80% of the patients, HPS occurred when immunosuppression was important: during the initial period after transplantation (first 6 months), after the treatment of acute rejection or during leucopenia related to CMV disease. In addition to treatment of the triggering factor, using anti-infectious agents, optimal therapy of HPS remains debated. Agents that modulate the immune response such as high-dose steroids, etoposide, plasma exchange or intravenous immunoglobulin have been reported with success but no controlled clinical trials of therapy have been done [39, 43] . In our series, all patients received only antituberculous treatment. Our study has several limitations. Firstly, we used a retrospective design. However, data collection was done specifically for this study and by the same investigator (E.C.) in the 14 centres. Secondly, we reported several cases unusable for the complete analysis because of missing data, which advocates the creation of a national registry to monitor infection in solid organ transplant. Thirdly, we included patients over a 20-year period, during which changes in treatment practices probably occurred. For instance, at hospital admission, all patients were taking corticosteroid therapy. The use of newer immunosuppressive agents such as sirolimus, mycophenolate mofetil, T-cell and B-cell depletion, and co-stimulatory blockade has lead to a substantial number of patients without longterm steroid therapy [3] . No firm conclusions can be drawn about risk factors because of the heterogeneity of our population. However, the aim of our study was to provide clinicians with data relevant to their everyday practice.
Therefore, we covered a long study period in order to report data from a large cohort. Strengths of our study include the multicentre design with 14 participating transplant centres, all of which had extensive experience with managing medical complications in kidney transplant recipients. Furthermore, we provide valuable epidemiological and clinical data on topics rarely reported.
In summary, TB occurred in 0.45% of kidney transplant recipients, most frequently in the first year. Disseminated and extrapulmonary TB accounted for two-thirds of cases. Overall prognosis was good with 6.1% of hospital mortality and 10 years graft survival of 67%. Although uncommon, HPS should always be suspected when fever and organomegaly are associated with pancytopenia because of its association with high mortality. We believe that the best strategy to avoid post-transplant TB is to improve the criteria for treatment of latent TB in the early post-transplant period. Our data suggest that treatment of latent TB should be considered for patients born in an area highly endemic for TB.
